Full Press Release Details
Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
SECURITIES EXCHANGE ACT OF 1934
Evotec Aktiengesellschaft
(Exact name of registrant as specified in its
Commission File Number: 001-34041
Schnackenburgallee 114
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7)
only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is
incorporated, domiciled or legally organized (the registrant s home country ), or under the rules of the home country exchange on which the registrant s securities are traded, as long as the report or other document is not a
press release, is not required to be and has not been distributed to the registrant s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
Table of Contents
| Item | Page | |
| Other Information | 3 | |
| Signatures | 3 | |
| Exhibit Index | 4 |
Table of Contents
On March 6, 2009, EVOTEC AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) issued a press release announcing the hiring of Dr. Werner Lanthaler
as Chief Executive Officer. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, thereunto duly authorized.
| Evotec AG | ||
| By: | /s/ Klaus Maleck | |
| Klaus Maleck | ||
| Chief Financial Officer |
Table of Contents
| Exhibit Number | Description | |
| 99.1 | Press Release dated March 6, 2009 |
Table of Contents
| March 6, 2009 | ||
| For further information please contact: Anne Hennecke Senior Vice President, Investor Relations & Corporate Communications +49.(0)40.560 81-286 +49.(0)40.560 81-333 Fax Anne.hennecke@evotec.com Evotec AG Schnackenburgallee 114 22525 Hamburg Germany www.evotec.com | Evotec Appoints Dr. Werner Lanthaler as Chief Executive Officer Hamburg, Germany Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the appointment of Dr. Werner Lanthaler as Chief Executive Officer of the Company, effective immediately. In his previous position, Dr. Lanthaler served as Chief Financial Officer of Intercell AG in Vienna, Austria, a global biopharmaceutical leader dedicated to the development of vaccines. In this role, he was also responsible for Business Development and Marketing & Sales. Dr. Lanthaler had eight very successful years at Intercell AG where he served since 2001. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr. Lanthaler played a pivotal role in many of the company s major corporate milestones including the most recent product approval of Intercell s Japanese En-cephalitis Vaccine, the company s acquisitions and strategic pharma part-nerships, as well as the company s Initial Public Offering on the Vienna Stock Exchange in 2005. Previously, Dr. Lanthaler served as Director of the Federation of Austrian Industry and as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in economics from Vienna University, earned his Master s degrees from Harvard University, and holds a degree in Psychology. Dr. Flemming rnskov, Chairman of the Supervisory Board of Evotec, stated: Dr. Lanthaler is an ideal candidate to be CEO of Evotec at this juncture. His experience in building a highly successful company, his im-pressive track record in business and corporate development, and his strong sense for the creation of shareholder value are a perfect match with Evotec s strategy to transform itself into a streamlined biopharmaceutical company. In summary, he brings all the skills and experience needed in order to adapt and shape Evotec s strategy and move the Company to the next level of success. I look forward to joining this exciting company in a challenging market environment. It possesses an abundance of opportunities based on good fundamental science, an excellent reputation for drug discovery and devel-opment, and strong financial resources. It is my goal to advance Evotec s vision and generate significant shareholder value in the years to come , stated Dr. Werner Lanthaler, the Chief Executive Officer of Evotec . |